Stockscreener 앱 받기
12.11
0.90%
-0.11
시간 외 거래:
12.08
-0.03
-0.25%
Contineum Therapeutics Inc 주식(CTNM)의 최신 뉴스
Bond Watch: Will Corvus Pharmaceuticals Inc stock go up in YEAR2026 Levels & Daily Entry Point Trade Alerts - baoquankhu1.vn
Revenue Check: Is FKWL still a buy after recent gainsStock Surge & Detailed Earnings Play Alerts - baoquankhu1.vn
Contineum Therapeutics, Inc. $CTNM Shares Sold by Baker BROS. Advisors LP - MarketBeat
Contineum Therapeutics Highlights PIPE-791 IPF Trial, J&J-Backed PIPE-307 Catalysts at Leerink Conference - MarketBeat
Baird Maintains Contineum Therapeutics (CTNM) Outperform Recommendation - MSN
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Contineum Therapeutics, Inc.Common stock (NQ: CTNM - The Chronicle-Journal
Certain Options of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
6,083,338 Class B common stock of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
Contineum’s MS drug falls short in Phase II trial - MSN
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Contineum Therapeutics, Inc. Class A (CTNM) and Aktis Oncology, Inc. (AKTS) - The Globe and Mail
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Contineum Therapeutics, Inc. Class A Common Stock share price - Mint
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com India
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - TipRanks
Contineum Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
CTNM: Phase 2 IPF trial dosing started, $93M raised, and cash runway extends into mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
USD News Center - University of San Diego
Contineum Therapeutics Faces Downgrade Following Clinical Trial Setback () - aktiencheck.de
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares By Investing.com - Investing.com South Africa
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock - Investing.com
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares - Investing.com
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock By Investing.com - Investing.com UK
Contineum Therapeutics (CTNM) CSO sells shares under 10b5-1 plan - Stock Titan
Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1 - Stock Titan
Beat the Market with Zacks: Spotlight on Contineum Therapeutics, Suzano, and PepsiCo - Bitget
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus - Yahoo Finance
Earnings Beat: Is Contineum Therapeutics Inc gaining market shareJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 7,100 shares, exercises options - Stock Titan
Contineum Therapeutics (CTNM) CSO exercises options and sells 8,124 shares - Stock Titan
Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday - MarketBeat
CTNM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Contineum Therapeutics Inc gaining market shareEarnings Summary Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
1.20%
0.06%
자본화:
|
볼륨(24시간):